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Abstract: The ketone body beta‐hydroxybutyrate (βHB) is a histone deacetylase (HDAC) inhibitor and has been shown to
be protective in many disease models, but its effects on aging are not well studied. Therefore we determined the effect of
βHB supplementation on the lifespan of C. elegans nematodes. βHB supplementation extended mean lifespan by
approximately 20%. RNAi knockdown of HDACs hda‐2 or hda‐3 also increased lifespan and further prevented βHB‐
mediated lifespan extension. βHB‐mediated lifespan extension required the DAF‐16/FOXO and SKN‐1/Nrf longevity
pathways, the sirtuin SIR‐2.1, and the AMP kinase subunit AAK‐2. βHB did not extend lifespan in a genetic model of
dietary restriction indicating that βHB is likely functioning through a similar mechanism. βHB addition also upregulated
ΒHB dehydrogenase activity and increased oxygen consumption in the worms. RNAi knockdown of F55E10.6, a short chain
dehydrogenase and SKN‐1 target gene, prevented the increased lifespan and βHB dehydrogenase activity induced by βHB
addition, suggesting that F55E10.6 functions as an inducible βHB dehydrogenase. Furthermore, βHB supplementation
increased worm thermotolerance and partially prevented glucose toxicity. It also delayed Alzheimer’s amyloid‐beta
toxicity and decreased Parkinson’s alpha‐synuclein aggregation. The results indicate that D‐βHB extends lifespan through
inhibiting HDACs and through the activation of conserved stress response pathways.

INTRODUCTION

cellular macromolecules as outlined in
mitochondrial free radical theory of aging [9].

Aging leads to a progressive decline of cell and tissue
function and is the primary risk factor for many
ailments, including the prevalent neurodegenerative
disorders Alzheimer’s disease (AD) and Parkinson’s
disease (PD). Mitochondria are the central hub of
cellular metabolism and mitochondrial dysfunction,
especially in stem cells [1], has been shown to cause the
development of premature aging phenotypes in mice
[2]. Paradoxically, slight inhibition of mitochondrial
respiration can also lead to small increases in reactive
oxygen species (ROS) production and extend the
lifespan of yeast, C. elegans, Drosophila, and mice [36]. Even in young animals, roughly 0.15% of electrons
passing through the mitochondrial electron transport
chain (ETC) combine with molecular oxygen to form
superoxide [7, 8]. Mitochondrial ROS production
increases with age and leads to progressive damage of
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the

Dietary restriction (DR) increases the lifespan of many
organisms including C. elegans [10]. As interest in the
molecular mechanisms responsible for the effect of DR
on lifespan have expanded, so has the discovery of the
pathways involved and the search for DR mimetic
compounds that promote survival and stress resistance
[11, 12]. The ketone body beta-hydroxybutyrate (βHB)
has been described as a DR mimetic compound [13], in
part because it increases in the plasma during DR and
when administered exogenously leads to decreased
levels of oxidative stress [14]. In mammals, βHB is
produced in the liver, primarily from the catabolic
breakdown of fatty acids, and is used as an alternative
energy source when blood glucose is low. This is
especially important in the brain where only a very
limited amount of fatty acid beta-oxidation takes place
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[15].
In mitochondria βHB is catabolized to
acetoacetate by βHB dehydrogenase 1 (BDH1). The
reaction is linked to the reduction of NAD to NADH,
which fuels mitochondrial ETC complex I.
The
resulting acetoacetate is catabolized to acetoacetyl-CoA
and then to acetyl-CoA, which is metabolized as part of
the TCA cycle. The βHB dehydrogenase 2 (BDH2)
enzyme localizes to the cytoplasm, but no changes in
ketone body metabolism were found in BDH2 knockout
mice suggesting BDH2 plays a limited role, if any, in
ketone body metabolism [16].

protection against neurodegeneration and motor
deficiency induced by the neurotoxin 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine
(MPTP),
which
induces PD-like symptoms [30]. Additionally, βHB
protected cultured neurons from toxicity induced by the
structurally related ETC complex I inhibitor 1-methyl4-phenylpyridinium (MPP(+)) [21]. In human clinical
trials, PD patients treated with a ketogenic diet for one
month improved their Unified Parkinson’s Disease
Rating Scale scores by a mean of 43% [31].
Although much is known about the effects of βHB on
neurodegenerative and other aging-associated diseases,
not much is known about its effects on aging.
Moreover, the mechanisms through which βHB are
protective are not entirely clear. However, recent
evidence suggests that βHB protects against oxidative
stress through its action as a class I and class IIa histone
deacetylase inhibitor to increase expression of stress
response genes such as FoxO3A and MT2 [14]. In this
report we determined the effect of βHB on lifespan in
C. elegans and determined the cytoprotective signaling
pathways required for this effect. We then determined
the effects of βHB on proteotoxicity in nematode
models of AD, PD, and amyotrophic lateral sclerosis
(ALS).

Researchers are investigating DR mimetics not only for
their possible lifespan extending capabilities, but also
for their potential ability to delay the onset and
progression of age-associated diseases such as AD. [17,
18]. Phenotypes of AD brain include extracellular senile
plaques containing Aß peptide as well as intracellular
neurofibrillary
tangles
consisting
of
hyperphosphorylated tau protein [19]. Intracellular Aß can
inhibit mitochondrial ETC complex IV and increase
ROS production [20]. βHB has shown some efficacy in
the protection against AD-mediated neurodegeneration
in animal models and human trials.
βHB protected
cultured hippocampal neurons from Aß 1–42 toxicity
[21]. βHB or a ketogenic diet has shown mixed effects
on disease phenotypes in mouse models of AD. For
example in one study, a ketogenic diet lowered Aß
levels, but did not affect cognitive impairment [22]. In
another study a ketogenic diet improved motor function,
but did not affect cognition or tau or Aß pathology [23].
However, a further study found that supplementation of
βHB methyl ester to AD mice was able to restore
cognitive function and decrease Aß levels, likely due to
the fact that the methyl ester is transported through the
blood-brain barrier more efficiently than the free acid
[24]. There is also evidence for the clinical use of
ketone bodies to treat neurodegenerative disorders as
oral ingestion of medium chain triglycerides, which are
catabolized in part to ketone bodies, increased plasma
levels of βHB and led to improved cognitive function in
human patients with AD [25].

RESULTS
D-beta-hydroxybutyrate extends the lifespan of C.
elegans
Addition of 2, 10, or 20 mM DL-beta-hydroxybutyrate
(βHB) to the culture medium of C. elegans feeding on
heat-killed E. coli increased lifespan with 20 mM
having the greatest effect, increasing mean lifespan by
26%, from 17.2 to 21.7 days (Figure 1A). 50 mM and
100
mM
concentrations
decreased
lifespan
(Supplementary Table 1).
Therefore a 20 mM
concentration was used in further experiments. When
C. elegans were fed live E. coli, 20 mM βHB only
extended mean lifespan by 14%, from 16.0 to 18.3 days.
This is likely due to catabolism of a portion of the βHB
by the bacteria. To determine if the lifespan extension
was due to D-βHB or L-βHB, we performed lifespan
experiments with each isomer separately and found that
only D-βHB addition resulted in lifespan extension
(Figure 1B).

PD, another aging-associated disorder, is characterized
by an accumulation of Lewy bodies in the substantia
nigra region of the brain. The alpha-synuclein protein is
a major component of Lewy bodies and can also
localize to mitochondrial membranes [26] causing
decreased ETC complex I activity with an
accompanying increase in ROS production [27]. This
may be partly responsible for the increased
mitochondrial oxidative damage that has been observed
in brains from autopsied PD patients [28, 29]. βHB has
also been shown to be efficacious in several animal
models of PD. Mice treated with βHB showed partial
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βHB or butyrate individually, but not when
combined, extend the lifespan of C. elegans
The histone deacetylase (HDAC) inhibitors sodium
butyrate and valproic acid have been shown to extend
lifespan in C. elegans [32, 33]. Since βHB has a similar
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chemical structure as butyrate and since βHB has been
shown to inhibit class I and IIa histone deacetylases
(HDACs 1, 3, and 4) in mammals with a Ki of 2-5 mM
[13], we determined if βHB could further extend the
lifespan of sodium butyrate treated worms. As shown in
Figure 2A, and as previously found by others [33],
sodium butyrate extended lifespan, but strikingly the
combination of sodium butyrate and βHB led to a slightly
decreased lifespan. This data is consistent with the
possibility that βHB is functioning as an HDAC inhibitor
as HDAC inhibitors such as valproic acid are known to
cause decreased lifespan at higher concentrations in C.
elegans ([32] and Supplementary Table 1).
The
combination of sodium butyrate and βHB likely has an
additive inhibitory effect on HDAC activity, thereby
decreasing lifespan. βHB addition also decreased the
lifespan of worms treated with valproic acid
(Supplementary Table 1), likely through a similar
mechanism.

hda-6, hda-10, and hda-11, with hda-4 being the only
member of class IIa [35]. To determine if HDAC
inhibition plays a role in βHB-mediated lifespan
extension, we knocked down the 3 class I HDACs in C.
elegans by RNAi in the presence or absence of βHB and
determined the effect on lifespan. RNAi knockdown of
hda-1 had no effect on lifespan and βHB addition
extended lifespan, but to a lesser extent than in the
absence of knockdown (Fig. 2B). However, RNAi
knockdown of either hda-2 (Fig. 2C) or hda-3 (Fig. 2D)
extended C. elegans lifespan, by 13% and 16%
respectively, and prevented βHB from further extending
lifespan. Therefore βHB likely extends lifespan in part
through inhibition of hda-2 and hda-3. We also
performed lifespan analysis using hda-2(ok1479), hda3(ok1991), hda-4(ok518), and hda-10(ok3311) mutant
worms (Supplementary Figure 1A-D). All of the HDAC
mutant strains had roughly 30% decreased mean
lifespans indicating that a partial knockdown, but not
full knockout of HDA-2 or HDA-3 activity promotes
lifespan extension. Consistent with the RNAi
knockdown results, βHB addition did not extend the
lifespan of the hda-2 or hda-3 mutant animals.
However, βHB addition did lead to lifespan extension in
the hda-4 and hda-10 mutants, suggesting βHB
primarily extends lifespan through inhibiting the class I
HDACs in C. elegans.

Inhibition of HDA-2 and HDA-3 play a role in βHBmediated lifespan extension
Many general HDAC inhibitors inhibit both class I and
class II HDAC enzymes [13, 34]. The C. elegans
genome has 3 class I HDACs, hda-1, hda-2, and hda-3.
In addition there are 5 class II HDACs, hda-4, hda-5,

Figure 1. D‐βHB extends the lifespan of N2 C. elegans worms. (A) Concentration
dependency of βHB‐mediated extension of lifespan. (B) D‐βHB, but not L‐βHB addition
led to lifespan extension. When no D or L prefix is present, βHB refers to DL‐βHB.
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Figure 2. βHB‐mediated HDAC inhibition plays a role in lifespan extension. (A) Survival of N2
worms in the presence of βHB, butyrate, or both compounds together. (B) Effects of hda‐1, (C) hda‐
2, or (D) hda‐3 RNAi knockdown on C. elegans lifespan in the presence or absence of 20 mM βHB.

F55E10.6 is likely
dehydrogenase gene

a

D-βHB

inducible

However, we found that adding D-βHB to the growth
medium resulted in a 2-fold increase in D-βHB
dehydrogenase activity and knockdown of F55E10.6
largely prevented this increased D-βHB dehydrogenase
activity (Fig. 3A), suggesting that F55E10.6 likely
encodes the D-βHB inducible D-βHB dehydrogenase
activity.
Knockdown of either dhs-2 or dhs-16
increased the ability of D-βHB to upregulate D-βHB
dehydrogenase activity. We also found that adding LβHB to the culture medium resulted in a roughly 3-fold
increase in D-βHB dehydrogenase activity in the worm
extracts that was independent of the expression of
F55E10.6, dhs-2, dhs-16, or dhs-20 (Figure 3B),
suggesting L-βHB induces a separate D-βHB
dehydrogenase enzyme. Consistent with this data,
when worms were cultured with a racemic mixture of
20 mM βHB (DL-βHB) we found an almost additive
4.5-fold increase in D-βHB dehydrogenase activity
(data not shown).

βHB

There is no strong homolog of human mitochondrial
BDH1 in C. elegans. However, a BLASTP search
identified 4 candidate genes with 38-41% protein
sequence identity with BDH1 (dhs-2, dhs-20, dhs-16 (a
3-hydroxysteroid dehydrogenase [36]), and F55E10.6
(similar to human microsomal retinol dehydrogenase
[37] and hydroxysteroid dehydrogenases [38]). DHS-2,
DHS-16, and DHS-20 have been predicted to have a
mitochondrial localization [39] like BDH1, however
DHS-20 has also been predicted to have an ER
localization [40] as has F55E10.6 [41]. Therefore, we
knocked down each of the 4 candidates individually in
the worms grown in the absence or presence of D-βHB
and measured D-βHB dehydrogenase activity in the
worm extracts. None of the knockdowns showed
decreased basal D-βHB dehydrogenase activity.
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Figure 3. D‐βHB dehydrogenase activity in worm extracts following RNAi‐mediated gene
knockdown. (A) D‐βHB dehydrogenase activity following worm culture in the absence or
presence of 10 mM D‐βHB. Conditions in the legend refer to the culture conditions. The genes
F55E10.6, dhs‐2, dhs‐16, or dhs‐20 were knocked down by RNAi feeding (* p < 0.05 compared to
Control + 10 mM D‐βHB; # p < 0.05 compared to Control). (B) D‐βHB dehydrogenase activity
following worm culture in the absence or presence of 10 mM L‐βHB. The assay conditions were
the same as panel A (# p < 0.05 compared to Control).

We also measured L-βHB dehydrogenase activity in
the worm extracts (Supplementary Figure 2). There
was roughly 5-fold lower basal L-βHB dehydrogenase
activity than D-βHB dehydrogenase activity in the
worm extracts (data not shown). Adding D-βHB to
the culture medium yielded a roughly 50% increase in
L-βHB dehydrogenase activity in control worm
extracts that was almost completely blocked by RNAi
knockdown of F55E10.6. Therefore, the F55E10.6
βHB dehydrogenase activity can likely utilize either

www.impactaging.com

D-βHB or L-βHB as substrates, but the activity with
D-βHB appears roughly 10-fold higher than with LβHB. Interestingly, knockdown of dhs-2, dhs-16, or
dhs-20 decreased basal L-βHB dehydrogenase
activity in the extracts (Supplementary Figure 2).
Determining whether any of these genes play a direct
role in L-βHB metabolism, or if a gene encoding an
enzyme with L-βHB dehydrogenase activity is downregulated by knockdown of these genes awaits further
investigation.

625

AGING, August 2014, Vol. 6 No.8

Figure 4. F55E10.6 is required for βHB‐mediated lifespan extension, but not for βHB‐induced
oxygen consumption. (A) Treatment with βHB did not increase the lifespan of N2 worms fed
RNAi to F55E10.6. (B) The addition of N‐acetyl‐L‐cysteine (NAC) did not decrease the lifespan of
βHB treated worms. (C) The effect of 20 mM βHB and RNAi knockdown of F55E10.6 on oxygen
consumption (* p < 0.05 vs. untreated; # p < 0.05 vs. Control). (D) The effect of 20 mM βHB
treatment on ATP levels in day 4 N2 worms (p = 0.202). Data are represented as mean +/‐ SEM.

F55E10.6 is required for βHB-mediated longevity

induces expression of F55E10.6. F55E10.6 could either
metabolize βHB or metabolize another endogenous
substrate leading to lifespan extension.

To determine if βHB-mediated upregulation of
F55E10.6 was essential for the effect of βHB on
longevity, lifespan was monitored in worms in which
expression of F55E10.6 was knocked down by RNAi
feeding. RNAi knockdown of F55E10.6 increased
lifespan by 7% and unexpectedly completely prevented
lifespan extension induced by βHB supplementation
(Figure 4A). F55E10.6 is a SKN-1 transcriptional
target [42]. SKN-1 is a homolog of mammalian Nuclear
factor (erythroid-derived 2)-like 2 (Nrf2) and a
transcriptional regulator that induces the expression of
genes involved in antioxidant defense and xenobiotic
metabolism to promote longevity. Therefore, addition
of βHB to the culture media activates SKN-1, which
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It is possible that metabolism of βHB, either dependent
or independent of F55E10.6, is required for lifespan
extension.
This increased βHB metabolism may
increase TCA cycle and electron transport chain (ETC)
activity increasing ROS production, which has been
shown to lead to lifespan extension in C. elegans [43].
Therefore we determined if administration of the
antioxidant and glutathione precursor N-acetylcysteine
(NAC) prevented the lifespan extension induced by
βHB.
As shown in Figure 4B, NAC by itself
moderately
increased
lifespan,
but
NAC
supplementation did not prevent lifespan extension
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mediated by βHB. Therefore, βHB is likely extending
lifespan through a mechanism that does not require
increased ROS production.

suggesting that F55E10.6 represses mitochondrial
biogenesis or respiratory function. But RNAi knockdown of F55E10.6 did not decrease the βHB-mediated
increase in oxygen consumption. The results suggest that
the metabolism of βHB by F55E10.6 does not play a
significant role in the use of βHB as an energy substrate
for respiration, and so other mechanisms likely explain
the requirement of F55E10.6 for lifespan extension.

Knockdown of F55E10.6 does not prevent the βHBmediated increase in oxygen consumption
Since F55E10.6 expression was essential for βHBmediated lifespan extension, we wished to determine if
supplemented βHB was being utilized as a respiratory
substrate by the worms and whether knocking down
F55E10.6 would decrease βHB-induced respiratory
metabolism. Therefore, we determined the effect of βHB
supplementation on worm oxygen consumption (Figure
4C). βHB supplementation increased oxygen consumption by 2.3 fold indicating that βHB is being
metabolized by the worms. Unexpectedly, we found that
RNAi knockdown of F55E10.6 in the absence of βHB
also increased oxygen consumption by around 2.3 fold,

We also determined the effect of βHB addition on worm
ATP levels (Figure 4D). ATP levels were not
significantly altered by βHB addition, although oxygen
consumption rates increased suggesting that βHB either
stimulates energy utilization pathways or decreases the
coupling efficiency of oxidative phosphorylation. In
this regard, we have previously shown that growth of C.
elegans in the presence of the TCA cycle metabolites
malate or fumarate resulted in a partial uncoupling of
mitochondria [44].

Figure 5. SKN‐1 and DAF‐16 are required for βHB‐mediated lifespan extension (A) βHB addition
did not increase the lifespan of N2 worms fed RNAi to knockdown expression of skn‐1. (B) βHB
addition increased fluorescence of the gst‐4::gfp SKN‐1 reporter strain. Data are represented as
mean +/‐ SEM (* p < 0.05). (C) βHB addition did not increase lifespan in daf‐16(mgDf50) mutant
worms. (D) βHB or butyrate increased fluorescence when administered to the sod‐3::gfp DAF‐16
reporter strain. Data are represented as mean +/‐ SEM (* p < 0.05).
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cycle metabolites citrate, succinate, fumarate, malate, or
oxaloacetate also failed to induce GFP expression
(Supplementary Figure 3B) suggesting that C. elegans
HIF-1 may be regulated slightly differently than
mammalian HIF-1.

SKN-1 and DAF-16 are required for βHB-mediated
longevity
To determine other molecular pathways through which
βHB functions to extend lifespan, we performed
lifespan experiments using worms deficient in common
longevity pathways.
In C. elegans the SKN-1
transcriptional activator is normally sequestered in the
cytoplasm by WDR-23 and the DDB1/CUL4 ubiquitin
ligase complex until the presence of specific
xenobiotics or reactive oxygen species leads to a
disruption of the interaction. This allows nuclear
translocation of SKN-1 leading to the activation of a
phase II detoxification transcriptional response and
lifespan extension [45, 46]. We next determined if βHB
extended the lifespan of worms in which SKN-1 levels
were knocked down by RNAi feeding. Consistent with
a role for SKN-1 and SKN-1 transcriptional targets such
as F55E10.6 in βHB-mediated longevity, βHB did not
extend the lifespan in these SKN-1 RNAi worms
(Figure 5A). Additionally βHB was able to increase
GFP fluorescence in the gst-4::gfp SKN-1 reporter
strain of worms (Figure 5B) supporting this assertion.
βHB was also able to induce expression of this reporter
strain following knockdown of the F55E10.6 gene
suggesting that F55E10.6 functions downstream of
SKN-1 in the longevity pathway, as is expected for a
SKN-1 transcriptional target.

βHB increases thermotolerance
Since lifespan extension, and DAF-16 and SKN-1
activation in particular, has been linked to stress
resistance, we determined the effect of βHB
supplementation on thermotolerance in C. elegans. As
shown in Figure 6, βHB administration extended the
mean survival time of the worms after they were shifted
to an elevated temperature by 22%. Due to the
increased thermotolerance we hypothesized that heat
shock proteins were induced by βHB supplementation.
Therefore we monitored GFP fluorescence in 4 heat
shock reporter strains of worms following βHB
treatment (Supplementary Figure 4A-D). We used the
strains hsp-6::gfp and hsp-60::gfp to monitor the
mitochondrial unfolded protein response [51], hsp4::gfp to monitor ER stress, and hsp-16.2::gfp to
monitor heat shock factor-1 (HSF-1)-mediated gene
expression [52]. βHB supplementation did not induce
expression of any of these four reporter strains.
Therefore βHB supplementation does not induce a
broad heat shock response, even though thermotolerance was increased.

Disruption of the DAF-2 insulin receptor signaling
pathway is known to extend lifespan through activation
of the DAF-16 transcriptional activator. DAF-16 is
homologous to mammalian FOXO genes.
βHB
supplementation to worms homozygous for the daf16(mgDf50) null allele did not lead to lifespan extension
(Figure 5C).
Furthermore, βHB supplementation
slightly increased fluorescence of the sod-3::gfp DAF16 reporter strain of worms (Figure 5D), supporting the
ability of βHB treatment to activate DAF-16 activity for
lifespan extension. Butyrate treatment also led to a
similar small increase in GFP fluorescence of the sod3::gfp worms suggesting a similar mechanism through
which βHB and butyrate extend lifespan.
Another transcriptional regulator linked to longevity is
hypoxia inducible factor-1 (HIF-1) [47].
We
hypothesized that βHB catabolism would increase the
concentration of TCA cycle metabolites that inhibit the
alpha-ketoglutarate-dependent degradation of HIF-1 by
the proteasome [48, 49] initiated by the EGL-9 prolyl
hydroxylase [50]. However, we found that βHB
supplementation did not increase fluorescence in the
nhr-57::gfp reporter strain [47] for HIF-1 transcriptional
activity (Supplementary Figure 3A). In addition
supplementation with 10 mM pyruvate, or the TCA
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Figure 6. Treatment with βHB increases thermotolerance (log‐
rank p < 0.001) in N2 worms when upshifted from 20°C to 35°C.
βHB mean survival time = 5.7 hours. Control mean survival time
= 4.5 hours.
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Decreased protein synthesis rates likely contribute to
βHB-mediated lifespan extension

There was a 5% mean lifespan extension in the βHBtreated rsks-1 mutant and a 8% mean lifespan extension
in the βHB-treated gcn-2 mutant compared to the 26%
lifespan extension in the βHB-treated N2 control.
Therefore, the ability to decrease translation rates
through both the TOR/RSKS-1 and GCN-2 pathways
likely allows for full βHB-mediated lifespan extension
in the wild-type N2 animals.

Recently it has been recognized that several of the
common longevity pathways converge to decrease the
rate of translation initiation to extend lifespan [53, 54].
This can occur through several mechanisms including
preventing phosphorylation of ribosomal protein S6 by
S6 kinases of the TOR signaling pathway, blocking
phosphorylation of eukaryotic initiation factor 4E
(eIF4E) binding proteins (4E-BPs) by the TOR kinase,
or by activation of general control nonderepressible 2
(GCN2) kinase. GCN2 activation can occur in the
presence of uncharged tRNAs due to amino acid
restriction [55] or during times when mitochondria
produce high levels of reactive oxygen species [56]. C.
elegans appears to lack close functional homologs of
mammalian 4E-BPs [57] (although one distant homolog
has been reported [58]), so they likely control the rate of
translation initiation mainly through the p70 S6 kinase
homolog RSKS-1 and the worm GCN2 homolog GCN2. Therefore, we obtained the mutant strains rsks1(ok1255) and gcn-2(ok871) and performed lifespan
analysis in the absence or presence of βHB. The
untreated lifespan of the rsks-1 mutant was greater than
that of the N2 control (Figure 7A) as expected, while
the untreated lifespan of the gcn-2 mutant was less than
the N2 control (Fig. 7B). With either strain, we found
that βHB-mediated lifespan extension was greatly
blunted compared to the effect on the N2 control strain.

Figure 8. βHB extends the lifespan of short‐lived mitochondrial
ETC complex I and complex II mutants. (A) gas‐1(fc21) survival in
the absence and presence of βHB. (B) mev‐1(kn1) survival in the
absence and presence of βHB.

ETC Complex I function is needed for full βHBmediated lifespan extension
Following mitochondrial βHB dehydrogenase function,
acetoacetate is converted to acetoacetyl-CoA with the
concurrent conversion of succinyl-CoA to succinate as a
byproduct of the succinyl-CoA: 3-ketoacid CoA
transferase reaction.
Because of this succinate
production, it has been suggested that βHB protected a
PD cell model by increasing mitochondrial ETC
complex II (succinate dehydrogenase) activity,
bypassing the ETC complex I deficits present in the
disease [30]. To determine if normal mitochondrial
ETC complex I or complex II activity is required for
βHB-mediated lifespan extension, we determined the
effect of βHB supplementation on the lifespan of shortlived complex I-defective gas-1(fc-21) mutants [59]
(Figure 8A) and short-lived complex II defective mev1(kn1) mutants [60] (Figure 8B). βHB extended the
lifespan of the gas-1 mutant by 11%, but not to the full
26% extent observed in wild-type worms. Therefore,

Figure 7. A decreased rate of protein synthesis contributes to
βHB‐mediated longevity. (A) βHB‐mediated lifespan extension
was blunted in rsks‐1(ok1255) mutant worms. (B) βHB‐mediated
lifespan extension was also blunted in gcn‐2(ok871) mutant
worms.
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normal ETC complex I function is necessary for the full
effect of βHB on longevity. βHB supplementation fully
extended the lifespan of mev-1 mutants indicating that
βHB does not require normal ETC complex II function
to extend lifespan.

mammals and increased βHB levels may be responsible
for some portion of the increased stress and disease
resistance conferred by CR, we determined the effect of
βHB supplementation on lifespan in the nematode eat2(ad1116) model of dietary restriction (DR) in which
pharyngeal pumping is slowed (Figure 9C). We found
that treatment with βHB had no significant effect on the
longevity of eat-2 worms suggesting that βHB extended
lifespan using some of the same downstream effectors
activated in DR. The CREB binding protein-1 (CBP-1)
transcriptional co-activator and protein acetyltransferase
has been shown to be essential for DR-mediated
longevity in C. elegans [33]. Therefore we determined
the effect of βHB on lifespan in worms where cbp-1
expression was knocked down by RNAi (Fig. 9D).
Consistent with βHB extending lifespan in a manner
similar to DR, knocking down cbp-1 prevented lifespan
extension induced by βHB treatment.

βHB-mediated longevity requires AAK-2, SIR-2.1,
CBP-1, and may occur in a similar manner as in DR
To identify if other important longevity regulators are
required for βHB-mediated longevity, βHB was
supplemented to AMP kinase (AMPK) aak-2(TG38)
mutant worms (Figure 9A) and sir-2.1(ok434) NADdependent protein deacetylase mutant worms (Figure
9B) and lifespan was monitored. βHB addition did not
extend the lifespan of either strain suggesting that both
proteins play a role in βHB-mediated longevity. Since
ketone body levels rise during caloric restriction (CR) in

Figure 9. βHB extends lifespan in a similar manner as DR and requires AAK‐2, SIR‐
2.1, and CBP‐1. (A) βHB does not extend lifespan of AMPK mutant aak‐2(TG38)
worms, (B) sir‐2.1(ok434) worms, or (C) eat‐2(ad1116) worms. (D) Additionally,
βHB does not extend the lifespan cbp‐1 RNAi knockdown N2 worms.
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Figure 10. βHB protects against glucose toxicity and proteotoxicity. (A) Treatment with βHB
partially protects against 50 mM glucose‐induced reduction of lifespan in N2 worms. (B) Survival of
the CL4176 strain of C. elegans expressing Aβ in muscle following temperature upshift. Treatment
with βHB increases the time to paralysis (log‐rank p < 0.001). βHB‐treated mean lifespan = 29
hours, untreated control mean lifespan = 26 hours. The curves are generated from the results of six
assays (n > 500 for both groups). (C) Treatment with βHB decreases α‐synuclein‐GFP aggregation in
the NL5901 strain GFP fluorescence readings were taken on day 8 of worm lifespan. Data are
represented as mean +/‐ SEM. (log‐rank p < 0.001) (D) 20 mM βHB did not protect against the
shortened lifespan induced by human TDP‐43 overexpression when the worms were grown at 16°C.

Many of the same compounds that extend lifespan in C.
elegans in a CBP-1 dependent manner also protect
against glucose toxicity [61]. It’s been shown that C.
elegans shows a reduced lifespan when grown in a high
glucose containing media [62-64]. When we grew
worms in 50 mM glucose, lifespan was decreased by
roughly 30% (Figure 10A). βHB supplementation to
the glucose-containing media partially restored the
lifespan, resulting in a lifespan reduction of only 21%
compared to the non-glucose treated controls.

within body wall muscle upon temperature upshift from
16° to 25°C, which leads to paralysis of all worms by
32 hours after upshift [65]. Figure 10B shows the
paralysis over time in these worms in the presence and
absence of βHB treatment. βHB increased the mean
paralysis time following Aß induction by 15%, from
approximately 26 to 30 hours.
Since βHB
supplementation was beneficial in this model of
proteotoxicity, we next determined the effects of βHB
administration on a PD-model worm strain expressing
human α-synuclein fused to yellow fluorescent protein
(YFP) in the body wall muscle [66]. Alpha-synuclein
protein is prone to aggregation and is the major protein
constituent of Lewy bodies in PD brain [67]. YFP
aggregation and fluorescence was decreased by 35% in
worms treated with βHB for 8 days, indicating a

βHB delays Aß-induced paralysis and decreases
alpha-synuclein aggregation
We next performed experiments using a strain of worms
engineered to express human AD-associated Aß peptide
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protective decrease in the levels of alpha-synuclein
aggregates (Figure 10C).

the enzyme does not likely possess a mitochondrial
localization producing NADH for ETC complex I
function. In this regard in addition to sharing homology
with mitochondrial BDH1, F55E10.6 shares homology
with microsomal retinol dehydrogenases [37] and
microsomal hydroxysteroid dehydrogenases [38]. Due
to these homologies and the role that SKN-1 plays in
controlling the ER stress response [41], F55E10.6 has
been putatively assigned an ER localization [41],
although no signal peptide was found [40]. Key to its
localization, F55E10.6 is predicted to have a
transmembrane domain [40].

A ketogenic diet has been shown to delay loss of motor
performance and loss of spinal cord motor neurons in
the SOD1-G93A mouse model of amyotrophic lateral
sclerosis (ALS) [68]. So lastly, we performed
experiments using worms overexpressing human TDP43 [69], which forms insoluble aggregates in the
nervous system of patients with ALS and other neurodegenerative disorders [70] and when expressed in the
nervous system of worms [69]. TDP-43 expression
caused a greatly reduced lifespan in C. elegans both
when grown at 20°C and when grown at 16°C (Supplementary Table 1). 20 mM βHB supplementation was
unable to prevent the reduction in lifespan (Figure
10D). Concentrations of βHB from 2 mM to 200 mM
were also tested (Supplementary Table 1). Only 30 mM
βHB was found to be effective at delaying toxicity and
the increase in longevity at this concentration was only
5%.

It is of interest that knockdown of F55E10.6, a SKN-1
target gene increased C. elegans oxygen consumption,
suggesting that SKN-1 signaling may decrease
mitochondrial biogenesis or function. Expression of
F55E10.6 has been shown to decline with aging [72],
likely due to the aging-related decline in activity of
SKN-1 [42]. The mammalian SKN-1 homolog Nrf2 is
also known to play a role in mitochondrial biogenesis.
When overexpressed Nrf2 was shown to be a negative
modulator of mitochondrial mass and membrane
potential in a high throughput screen using C2C12
myoblast cells [73]. However, when upregulated under
physiological conditions Nrf2 was found to be a
positive regulator of mitochondrial biogenesis by
inducing nuclear respiratory factor-1 (NRF-1) and
peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1α) expression in heart [74],
liver [75], and lung [76].

DISCUSSION
Administering βHB to C. elegans extended lifespan and
delayed proteotoxicity and glucose toxicity. βHB
extended C. elegans lifespan in a SIR-2.1 and AMPKdependent manner that also required the stressresponsive transcription factors DAF-16 and SKN-1.
Since βHB did not extend lifespan in eat-2 pharyngeal
pumping mutants, βHB likely acts as a dietary
restriction mimetic, as previously hypothesized for its
effects in mammals [71]. Even though protective effects
of D-βHB on rodent disease models are known, this is
the first report to identify D-βHB as a positive
modulator of organismal longevity in wild-type
animals. We also identified many of the signaling
pathways and genes required for this effect. A key
finding is that D-βHB-mediated lifespan extension
requires SKN-1 and its transcriptional target F55E10.6,
a short-chain dehydrogenase/reductase with βHB
dehydrogenase activity, although inhibition of HDACS
HDA-2 and HDA-3 are also required for the increased
longevity.

Full βHB-mediated lifespan extension requires
mitochondrial ETC complex I function
βHB-induced lifespan extension was partially blocked
in ETC complex I mutant worms and was unaffected in
mitochondrial ETC complex II mutant worms. This
likely suggests that the lifespan extension is driven
partly by βHB metabolism-independent effects and
partly by metabolism-dependent effects.
Normal
complex I activity may be needed to maintain a high
NAD/NADH ratio beneficial for maximal lifespan
extension [77]. In this regard, it has been shown that
rotenone can induce a roughly 10-fold reduction in C.
elegans respiration, but only a 2-fold reduction occurred
in the presence of 10 mM βHB [78]. Therefore, βHB
either stabilized complex I function in the presence of
rotenone or stimulated complex II-dependent respiration
to bypass this block of complex I function. In mammals
βHB has been shown to stabilize and increase the
efficiency of ETC complex I [68, 79]. The increased
rate of NADH oxidation in the presence of βHB led to
decreased ROS levels in mouse neocortical neurons
following glutamate excitotoxicity [79]. βHB may also

The role of F55E10.6 in βHB-mediated lifespan
extension
The βHB dehydrogenase enzyme assay data suggest
that F55E10.6 is a D-βHB-inducible βHBdehydrogenase enzyme. However, D-βHB may not be
the preferred physiological substrate for the enzyme or
the substrate required for lifespan extension. Since
knockdown of F55E10.6 did not affect the increased
oxygen consumption following βHB supplementation,
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enhance complex I activity in worms, but it may not be
able to fully do so in the gas-1 mutants preventing full
lifespan extension.

The second proposed model of how βHB may extend
lifespan is through inhibition of the insulin signaling
pathway. In mammals, it has been shown, contrary to
expectations, that βHB administration or a ketogenic
diet blocks the insulin signaling pathway in muscle
leading to insulin resistance [86]. This adaptation likely
evolved to allow the brain preferential use of the
bloodstream glucose during starvation. However, a
ketogenic diet has also been shown to be effective at
lowering blood glucose in patients with type II diabetes
due to the decreased carbohydrate intake [87]. In
mouse studies, βHB administration yielded a 50%
reduced phosphorylation and activity of Akt/protein
kinase B downstream of the insulin receptor decreasing
insulin signaling [86]. The mechanism for this βHBmediated inhibition of Akt and the insulin signaling
pathway was not fully elucidated, but it relied upon
administration of D-βHB and not L-βHB, suggesting
that mitochondrial metabolism of D-βHB may be
involved. In C. elegans, inhibition or decreased
expression of Akt or other proteins of the insulin
signaling pathway has been shown to activate both
DAF-16 and SKN-1 leading to lifespan extension [88],
thereby providing a potential mechanism for the effect
of βHB on longevity.

Proposed mechanism for βHB-mediated lifespan
extension
We propose 2 possible mechanisms for lifespan
extension mediated by βHB supplementation. In the
first mechanism (see Supplementary Figure 5), we
propose that βHB directly inhibits HDACs to increase
histone acetylation [14] causing gene expression
changes leading to SΚΝ−1 activation, independent of
βHB catabolism.
The metabolism-independent
activation of SKN-1 is consistent with our previous data
showing that stimulation of metabolism by
supplementation of several TCA cycle metabolites did
not activate SKN-1 transcriptional activity [44]. Next,
SKN-1 activity induces expression of F55E10.6 [42,
45], required for proper execution of the SKN-1
longevity program. SKN-1 activation has been shown
to repress expression of the insulin-like peptides DAF28 and INS-39, decreasing DAF-2 insulin receptor
signaling to activate DAF-16 [80]. βHB catabolism
also likely increases the level of specific TCA cycle
intermediates, which may contribute to the DAF-16mediated lifespan extension. We and others have
shown that supplementation of the TCA cycle metabolites fumarate, malate, and oxaloacetate activated
nuclear translocation of DAF-16 to extend lifespan in an
AMPK and SIR-2.1-dependent manner [44, 81]. Others
have also found that the TCA cycle metabolite alphaketoglutarate extends lifespan through a TOR kinasedependent mechanism [82]. Although this model is
consistent with our data, is also possible that βHBmediated HDAC inhibition causes a direct
transcriptional upregulation of DAF-16, as βHBmediated HDAC inhibition directly upregulates
expression of the DAF-16 homolog FOXO3A in
mammals [14].

βHB does not induce a broad heat shock response,
but still increases thermotolerance
Although βHB did not induce expression of four
specific heat shock proteins monitored (Supplementary
Fig. 3), it did activate the DAF-16 and SKN-1 signaling
pathways, which are both likely responsible for the
increased thermotolerance observed following βHB
treatment. Previous research has shown that RNAi
knockdown of either skn-1 or daf-16 decreased thermotolerance [89]. DAF-16 is known to induce expression
of several heat shock proteins including hsp-12.6, sip-1,
and hsp-16.1, which may play a role in the increased
thermotolerance. The factors that SKN-1 induce to
confer thermotolerance are less clear, although SKN-1
function has been implicated in the induction of hsp-4
expression and activation of the ER stress response
[41]. However, we did not find βHB to induce hsp4::GFP expression, but a positive trend was observed (p
= 0.18).

In addition, βHB metabolism may increase acetyl-CoA
levels that serve as a substrate for histone acetyltransferases to increase histone acetylation [83], which
could strengthen the effects of HDAC inhibition to
extend lifespan.
However, increased cytoplasmic
acetyl-CoA levels have also been shown to inhibit
autophagy [84], which could potentially dampen
lifespan extension. However, the acetyl group from
mitochondrial acetyl-CoA can be transferred to
carnitine to form acetylcarnitine and exported from
mitochondria to the nucleus, where acetyl-CoA is
reformed and used for nuclear histone acetylation [85].
This mechanism may allow for increased histone
acetylation without decreased rates of autophagy.
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Neuroprotective effects of ketone bodies
In an AD cell model, βHB has been shown to protect
hippocampal neurons from Aß toxicity [90]. The
protection may have occurred through decreasing ROS
levels as decreased ROS production is known to lower
expression levels of beta-secretase (BACE1), a protease
that contributes to toxic Aß generation [91]. This
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mechanism may be responsible for the ketogenic dietinduced reduction of Aß levels in a mouse model of AD
[22]. The brain’s ability to utilize glucose decreases in
AD. To prevent deficits in brain ATP levels, βHB has
been used as an alternative metabolic energy source for
patients with AD [25].
Increased inflammation
accompanies brain aging and may contribute to the
development of AD. Increased levels of ketone bodies
have been shown to reduce inflammation [71, 92] and
this may result from increased mitochondrial efficiency
and decreased ROS production [93].

Do βHB levels increase in DR worms and if so does this
play a role in DR-mediated longevity? Lastly, are the
same signaling pathways required for longevity also
required for βHB-mediated protection in the C. elegans
models of Aß and alpha-synuclein toxicity? Future
experiments will provide answers to these questions and
elucidate the molecular mechanisms responsible for the
protective effects of βHB. This knowledge will allow
for a broader use of βHB as a therapy for aging-related
disorders.
Conclusion

PD is associated with aggregation of alpha-synuclein
and death of dopaminergic neurons leading to motor
decline.
Mice treated with βHB showed partial
protection against neurodegeneration and motor
deficiency induced by MPTP [30]. Surprisingly, this
was not due to increased NADH generation fueling
complex I, but was described to be due to an increased
supply of succinate, a substrate for ETC complex II
[94]. As mentioned previously, the stimulation of
complex II activity by βHB metabolism depends on the
increased succinate produced as a byproduct of the
mitochondrial
succinyl-CoA:
3-ketoacid
CoA
transferase reaction.
However, since βHB fully
extended lifespan in complex II-defective mev-1
mutants, it is unlikely that this mechanism plays a
substantial role in βHB-mediated lifespan extension.
The mechanism of βHB-mediated protection in PD
models may be similar to the mechanism by which βHB
supplementation increases lifespan in the complex Idefective gas-1 worms.

βHB treatment extended lifespan and protected against
metabolic, proteotoxic and thermal stress in C. elegans.
βHB-mediated lifespan extension occurred through
induction of the DAF-16 and SKN-1 signaling
pathways and was dependent upon βHB-mediated
inhibition of HDACs HDA-2 and HDA-3. Our data
support the hypothesis that βHB is a DR mimetic and
that βHB treatment will likely be useful in the treatment
of many human aging-associated disorders.

MATERIALS AND METHODS
C. elegans strains. C. elegans strains were obtained
from the Caenorhabditis Genetics Center (CGC,
University of Minnesota) and were cultured at 20°C in
either liquid S media or NGM agar media [44] as
indicated. Lifespan assays were performed using the
following strains: N2 Bristol (wild-type), GR1307 [daf16(mgDf50)], TG38 [aak-2(gt33)], DA1116 [eat2(ad1116)], TK22 [mev-1(kn1)], CW152 [gas-1(fc21)],
VC199 [sir-2.1(ok434)], RB1206 [rsks-1(ok1255)],
RB967 [gcn-2(ok871)], VC983 [hda-2(ok1479)],
RB1618 [hda-3(ok1991)], RB758 [hda-4(ok518)], and
RB2416 [hda-10(ok3311)].
The following strains
expressing GFP were used to monitor promoter
activation:
CL2166
[pAF15(gst-4p::GFP::NLS)],
SJ4100
[hsp-6::gfp(zcIs13)],
SJ4058
[hsp60::gfp(zcIs9)], SJ4005 [hsp-4::gfp(zcIs4)], ZG449
[nhr-57p::GFP + unc-119(+)], and CL2070 [hsp-162::gfp(dvIs70)]. The following strains were used as
disease models: NL5901 [pkIs2386 (unc-54p::alphasynuclein::YFP + unc-119(+))], CL4176 [smg-1ts [myo3::Aβ1–42 long 3′-UTR]], and CL6049 [dvls62 (snb1::hTDP-43 + pCL26 (mtl-2::GFP)].

Study limitations and future directions
Although we were able to dissect many of the pathways
through which βHB extends lifespan in C. elegans,
many questions remain. For example, is the reason that
D-βHB but not L- βHB extended lifespan due to the
increased ability of D- βHB to be metabolized or due to
the higher efficiency of D-βHB as an HDAC inhibitor?
Is HDAC inhibition required for βHB-mediated
upregulation of SKN-1 or DAF-16 activity? In addition
to extending lifespan as shown here, RNAi knockdown
of the class I HDAC hda-3 was shown to protect against
polyglutamine-mediated toxicity in a C. elegans
Huntington’s disease, while knockdown of most other
HDACs increased toxicity [95]. Is HDAC inhibition or
SKN-1 activity required for DAF-16 activation by
βHB? Also is βHB catabolism required for βHBmediated SKN-1 or DAF-16 activation? Furthermore,
is the transcription factor PHA-4/FoxA, which is
required for DR-mediated longevity [96], also required
for βHB-mediated longevity? In this regard mammalian
Foxa2 is known to induce expression of BDH1 [97].
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Chemicals. Sodium DL-3-hydroxybutyric acid (βHB),
sodium butyrate, valproic (2-propylpentanoic) acid,
ethidium bromide, and potassium cyanide were
purchased from Acros Organics.
Sodium D-3hydroxybutyric acid and L-3-hydroxybutyric acid were
obtained from Sigma. 5-fluoro-2′-deoxyuridine (FUdR)
was purchased from Research Products International
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hydrazine hydrate, 1 μM rotenone, 10 mM NAD, 20 mm
D-βHB or L-βHB, and 10 μL of Halt protease inhibitor
cocktail (Thermo Scientific). Worms were grown with or
without D-βHB or L-βHB as indicated. On day 4 of
development, worms were washed 3 times with M9
buffer to free them of bacteria and condensed to 50
worms per microliter. 1 mL of concentrated worms was
subjected to 3 freeze-thaws cycles in liquid nitrogen. 50
μL of each sample (~ 2,500 worms) was added to a clear
bottomed 96-well microplate, followed by addition of
100 μL of the reaction mix above. NADH fluorescence
was measured kinetically for 20 minutes using 360/40
nm excitation and 460/40 nm emission filters (n=5) on a
Biotek Synergy 2 microplate reader.

Corp. and Biotang, Inc. Sodium hydroxide (Fisher
Scientific) was added to metabolite stock solutions to
obtain a pH of 7.0.
Lifespan Analysis. C. elegans adults were bleached as
previously described [44] to yield age-synchronized
eggs in S-medium. Lifespan experiments were
performed suspending eggs in liquid media in 3 µM
transparent cell culture inserts (BD Falcon #353181) in
12-well microplates on an orbital shaker at 135
rotations/min at 20°C [98]. 1.3 mL of S-medium
containing 9×109 HT115 (DE3) E. coli per mL was
placed in each well of a 12-well microplate. Then,
bleach synchronized worm eggs were suspended at a
concentration of 100–200 eggs/mL in the bacterial
suspension in S-medium. Lastly, a cell culture insert
was placed in each microplate well into which 0.25 mL
of the egg/bacterial suspension (25-50 eggs) was placed
(n = 3 wells per condition). Excluding RNAi lifespan
experiments, bacteria were heat killed (using a Kendal
model HB-S-23DHT ultrasonic cleaner) at 80°C for 60
minutes. Synchronized cultures of worms were cultured
at 20°C and monitored until they reached adulthood
(~72 h), at which time FUdR was added to a final
concentration of 400 µM. Worm viability was scored
every two days. Worms that did not respond to repeated
stimulus were scored as dead and those that contained
internally hatched larvae were excluded. The media
containing bacteria in the wells of the microplate into
which the culture inserts were submerged was removed
and replaced with a new bacterial suspension every 3
days.

Oxygen consumption measurements. N2 worms were
grown in 12-well cell culture plates and fed HT115
(DE3) control or F55E10.6 RNAi knockdownexpressing E. coli as food for 4 days in the absence or
presence of 20 mM βHB. Worms were washed 4 times
using M9 buffer to free them of the bacteria and then
resuspended in the culture media in which they were
grown except without the bacteria. The average
concentration of worms was obtained by taking ten 10
µL drops and counting the number of living worms in
each drop. The volume of the culture was then adjusted
to obtain a final concentration of 2 worms per µL. 300
µL of the worm suspension was then added to the
chamber of a Clark oxygen electrode (MT200A
chamber, Strathkelvin Instruments) and the respiration
was monitored for 5 minutes. The respiratory rate was
normalized to protein content by performing a protein
assay on the worm suspension.

High glucose lifespan assays. We performed lifespans as
described above with the addition 50 mM glucose to the
culture medium. Animals were scored every day and
inserts were transferred to fresh media every two days.

ATP level measurements. ATP levels were measured
using CellTiter-Glo reagent (Promega) on day 4 worms
grown in the absence or presence of 20 mM βHB
washed free of bacteria and then lysed by freeze-thaw as
described in [44].

RNAi treatment. The E. coli skn-1, cbp-1, hda-1, hda2, hda-3, F55E10.6, dhs-2, dhs-16, and dhs-20 clones
from the Ahringer C. elegans RNAi library (Source
BioScience LifeSciences), were grown for 16 hours and
then given 1 mM IPTG to induce expression of the
RNAi for 4 hours similarly as described in [99].
Lifespan experiments were performed as described
above with the exception that live bacteria were used
and the culture media in the microplate was replaced
daily to replenish metabolite levels that may be partially
depleted by bacterial metabolism.

GFP reporter strains. The GFP fluorescence of C.
elegans populations was assayed using a Biotek
Synergy 2 microplate reader.
Strains were age
synchronized and cultured in 12-well microplates as
described above. At the L3 stage of larval development
animals were treated with βHB or other compounds.
Following 24 hours of treatment, worms were washed 3
times in S-medium and approximately 400 worms per
200 µL were added to a clear 96-well microplate and
GFP fluorescence was measured using 485/20 nm
excitation and 528/20 nm emission filters (n=10 per
treatment group).

D-βHB or LβHB dehydrogenase assays.
βHB dehydrogenase activity was assayed as in [100],
slightly modified from the original method published in
[101]. The reaction mix contained 100 mM TrisHCl pH 8.0, 10 mM MgSO4, 5 mm K+ EDTA, 400 mM
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Microscopy and quantification.
Worms used for
microscopy were anesthetized in M9 media containing
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1mM levamisole and transferred to agar pads with glass
coverslips and analyzed using an EVOS fluorescence
microscope. Comparable results were established in the
absence of levamisole (data not shown). Approximately
20 worms per condition were used and experiments
were repeated at least three times (n=3). ImageJ™
software was used to quantify pixel densities.

2 hours. After two hours, adults were removed and
plates were placed in a 16°C incubator. At the L4 larval
stage worms were transferred onto treated or untreated
NGM plates with added 5-fluoro-2′-deoxyuridine
(FUdR, 0.05 mg/mL) to inhibit egg-laying and growth
of progeny. Worms were scored everyday by gentle
touch with a platinum wire. Failure to respond to touch
or move forward or backwards was scored as dead.

Thermotolerance assays. A synchronized population of
N2 C. elegans eggs was placed on 20 mM βHB treated
on non-treated NGM agar plates and allowed to hatch at
20°C. At the L4 larval stage of development animals
were transferred to a 35°C incubator. Survival was
scored as the number of animals responsive to gentle
prodding with a worm pick. 224 βHB-treated and 250
non-treated worms were counted.

Statistical Analysis. Kaplan-Meier survival analysis
and log-rank tests were performed using Sigmaplot
version 11.0. Student’s t-tests were used in other
analyses.
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Aß-mediated paralysis assays. Paralysis assays were
carried out as outlined in [65]. Briefly, second
generation synchronized gravid C. elegans strain
CL4176 were placed on treated or untreated 6 cm NGM
plates and allowed to lay eggs for 2 hours. After two
hours, adults were removed and plates were placed in a
16°C incubator for 48 hours. Following 48 hours,
plates were upshifted to a 25°C incubator. Scoring for
paralyzed worms began 20 hours after upshift. Animals
were scored for movement every two hours. Worms
were considered paralyzed if they could not complete a
full body movement after stimulation with a worm pick.
Alpha-synuclein protein aggregation assays. Eggs from
the NL5901 strain of C. elegans were treated with
alkaline bleach, washed, and then placed in 12 well cell
culture inserts as described above in the presence or
absence of βHB. Following 3 days of treatment, FUdR
was added to the inserts to prevent egg-laying and
progeny development. Culture media in the microplates
was changed every 3 days. On day 8 worms were
washed 3 times with M9 media and placed on 1%
agarose pads or immobilized with 10mM levamisole.
Visualization of the number of inclusions expressing
alpha-synuclein-YFP was captured using an EVOS
fluorescence microscope. Foci larger than 2 µm2 were
counted for each group (n=30) and measurements on
inclusions were performed using NIH ImageJTM
software and the assay was completed at least 3 times
similarly as performed in [102]. Statistical analysis was
completed using GraphPad Prism software and
calculation of statistical significance between various
groups was carried out by Student’s t-tests.
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SUPPLEMENTARY DATA

Supplementary Figure 1. The effect of βHB on lifespan in histone deacetylase mutants. βHB
addition did not extend the lifespan of (A) hda‐2(ok1479) mutant worms or (B) hda‐3(ok1991)
mutant worms. βHB addition extended the lifespan of (C) hda‐4(ok518) mutant worms (log‐rank p
=0.001) and (D) hda‐10(ok3311) mutant worms (log‐rank p =0.002).

Supplementary Figure 2. L‐βHB dehydrogenase activity in worm extracts grown in the absence or
presence of 10 mM D‐βHB. Knockdown of F55E10.6 almost completely prevented the increased L‐
βHB dehydrogenase activity induced by culturing with D‐βHB (* p < 0.05 vs. (Control + 10mM D‐
βHB)). Knockdown of dhs‐2, dhs‐16, or dhs‐20 decreased endogenous L‐βHB dehydrogenase activity
in the extracts (# p < 0.05 vs. Control).
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Supplementary Figure 3. βHB, pyruvate, or TCA cycle metabolites do not activate HIF‐1
transcriptional activity. The effect of (A) βHB, (B) pyruvate, or TCA cycle metabolites on GFP
fluorescence in nhr‐57::gfp worms. 20 M potassium cyanide was used as a positive control. (* p <
0.05).

Supplementary Figure 4. βHB addition does not induce expression of several heat shock
proteins. The effect of βHB addition on the fluorescence of (A) hsp‐6::gfp, (B) hsp‐60::gfp, (C) hsp‐
16.2p::GFP, or (D) hsp‐4::GFP worms. For (A) and (B) 50 _g/ml ethidium bromide treatment for 2
days was used as a positive control. For (C) and (D) heat shock at 35°C for 2 hours was used as a
positive control. (* p < 0.05).
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Supplementary Figure 5. One possible mechanism through which βHB may
extend lifespan in C. elegans.
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